Dy­nacure se­cures $55M as their Io­n­is-de­vel­oped drug moves in­to clin­ic

A month af­ter dos­ing their first ever pa­tient with their Io­n­is-li­censed tech, Dy­nacure has an­nounced a new round of fund­ing to ad­vance the tri­al.

The French biotech an­nounced €50 mil­lion ($55 mil­lion) in Se­ries C fund­ing, led by Per­cep­tive Ad­vi­sors. Al­though list­ed as a Se­ries C, it is the sec­ond tranche of cash the com­pa­ny has ever an­nounced, af­ter their ini­tial $55 mil­lion raise in 2018. The cash will float Dy­nacure through its Phase I/II tri­al in a class of neu­ro­mus­cu­lar dis­eases known as my­otubu­lar and cen­tronu­clear my­opathies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.